Rebecca Weil
Corporate Officer/Principal at OCULIS HOLDING AG
Rebecca Weil active positions
| Companies | Position | Start | End |
|---|---|---|---|
| OCULIS HOLDING AG | Corporate Officer/Principal | 2023-09-10 | - |
Career history of Rebecca Weil
Former positions of Rebecca Weil
| Companies | Position | Start | End |
|---|---|---|---|
| IDORSIA LTD | Sales & Marketing | 2019-06-30 | 2023-07-31 |
| SHIRE | Corporate Officer/Principal | 2016-07-31 | 2019-02-28 |
| Juvenile Diabetes Research Foundation (New York) | Director/Board Member | - | - |
| BAUSCH + LOMB CORPORATION | Sales & Marketing | - | - |
| NOVARTIS AG | Corporate Officer/Principal | - | - |
| ALCON INC. | Corporate Officer/Principal | - | - |
Training of Rebecca Weil
| Massachusetts Institute of Technology | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Statistics
International
| Switzerland | 5 |
| United States | 4 |
| Ireland | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Sales & Marketing | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 7 |
| Finance | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| ALCON INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| IDORSIA LTD | Health Technology |
| BAUSCH + LOMB CORPORATION | Health Technology |
| OCULIS HOLDING AG | Health Technology |
| Private companies | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Juvenile Diabetes Research Foundation (New York) |
- Stock Market
- Insiders
- Rebecca Weil
- Experience
